Fat Accumulation, Liver Fibrosis, and Metabolic Abnormalities in Chinese Patients With Moderate/Severe Versus Mild Hepatic Steatosis

Wei Zhang, Rui Huang, Yi Wang, Huiying Rao, Lai Wei, Grace L. Su, Anna S. Lok – 7 October 2019 – Several drugs in development for nonalcoholic fatty liver disease (NAFLD) aim to decrease the amount of fat in the liver. We compared quantity and quality of fat in subcutaneous, visceral and muscle compartments, liver fibrosis, and prevalence of metabolic abnormalities between Chinese patients with moderate/severe hepatic steatosis versus those with mild hepatic steatosis. NAFLD patients were prospectively recruited from Peking University People's Hospital in Beijing, China.

Longterm Outcomes of Living Donor Liver Transplantation for Glycogen Storage Disease Type 1b

Seiichi Shimizu, Seisuke Sakamoto, Reiko Horikawa, Akinari Fukuda, Hajime Uchida, Masahiro Takeda, Yusuke Yanagi, Rie Irie, Takako Yoshioka, Mureo Kasahara – 6 October 2019 – Glycogen storage disease (GSD) type 1b (Online Mendelian Inheritance in Man [OMIM] 232220) is an autosomal recessive inborn error of carbohydrate metabolism caused by defects in glucose‐6‐phosphate translocase. GSD1b patients have severe hypoglycemia with several clinical manifestations of hepatomegaly, obesity, a doll‐like face, and neutropenia.

LiverLearning®: 2019 Webinar: Liquid Biopsy in Hepatocellular Carcinoma: Applications in Surveillance and Prediction of Treatment Response

Liquid biopsy entails the analysis of tumor components released by cancer cells to biological fluids such as blood, saliva or cerebrospinal fluid. It has emerged as a promising source of novel biomarkers in the clinical management of patients with hepatocellular carcinoma. We will discuss the current developmental status of this technology and how it may change decision-making in patients with hepatocellular carcinoma. We will utilize a live webinar format that will be recorded for on-demand viewing on Liver Learning ® .Lewis R. Roberts Dr. Lewis R.

Subscribe to